Haydar A. Frangoul

Hematology | Oncology

2018 Clinch Ave
Knoxville, TN 37916

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 103 publications

Incidence of Human Leukocyte Antigen (HLA) Class I Antibodies and Impact on Platelet Engraftment, Transfusions and Bleeding in Recipients of Gene Therapy for Sickle Cell Disease and Transfusion Dependent Beta Thalassemia.

Incidence of Human Leukocyte Antigen (HLA) Class I Antibodies and Impact on Platelet Engraftment, Transfusions and Bleeding in Recipients of Gene Therapy for Sickle Cell Disease and Transfusion Dependent Beta Thalassemia.

Journal: Transplantation and cellular therapy

Published: July 02, 2026

Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease.

Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease.

Journal: The New England journal of medicine

Published: June 11, 2026

Risks and benefits of gene therapy and transplantation in sickle cell disease. Comment on: ,HLA-haploidentical hematopoietic stem cell transplantation in patients with sickle cell disease: results from the phase II DREP-HAPLO trial.

Risks and benefits of gene therapy and transplantation in sickle cell disease. Comment on: ,HLA-haploidentical hematopoietic stem cell transplantation in patients with sickle cell disease: results from the phase II DREP-HAPLO trial.

Journal: Haematologica

Published: June 04, 2026

Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion-Dependent β-Thalassemia.

Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion-Dependent β-Thalassemia.

Journal: American journal of hematology

Published: May 14, 2026

Is gene therapy a cure for β-thalassemia?

Is gene therapy a cure for β-thalassemia?

Journal: Blood

Published: May 07, 2026

CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia.

CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia.

Journal: The New England journal of medicine

Published: April 03, 2026

CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease.

CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease.

Journal: The New England journal of medicine

Published: April 03, 2026

Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease.

Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease.

Journal: The New England journal of medicine

Published: April 03, 2026

Prime Editing for p47phox-Deficient Chronic Granulomatous Disease.

Prime Editing for p47phox-Deficient Chronic Granulomatous Disease.

Journal: The New England journal of medicine

Published: December 08, 2025

Safety and Feasibility of Fertility Preservation and Fertility Outcomes in Patients with Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Undergoing Gene Therapy.

Safety and Feasibility of Fertility Preservation and Fertility Outcomes in Patients with Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Undergoing Gene Therapy.

Journal: Transplantation and cellular therapy

Published: June 01, 2025

Gene therapy for HbSC disease and other compound heterozygous sickle hemoglobinopathies: a time for inclusion.

Gene therapy for HbSC disease and other compound heterozygous sickle hemoglobinopathies: a time for inclusion.

Journal: Blood

Published: May 13, 2025

Efficacy of Total-Body Irradiation-based Intensified Myeloablative Regimens for Acute Leukemia-An International Collaborative Study.

Efficacy of Total-Body Irradiation-based Intensified Myeloablative Regimens for Acute Leukemia-An International Collaborative Study.

Journal: EJHaem

Published: April 03, 2025

Showing 1-12 of 103

Last Updated: 09/26/2026